Machine learning models for optimizing Critical Quality Attributes (CQAs) in cell therapy release testing

Cell therapies represent one of the most promising frontiers in regenerative medicine, offering curative potential for conditions previously deemed untreatable. Yet, their complex biological nature and the high variability of living cells create unique challenges in ensuring consistent safety, potency, and efficacy. Critical Quality Attributes (CQAs) including viability, identity, purity, and functionality form the backbone of regulatory approval and therapeutic effectiveness, making their optimization central to reliable release testing. Traditional approaches, heavily dependent on manual assays and time-consuming protocols, often struggle to provide the speed, accuracy, and scalability required to meet patient needs and evolving regulatory demands. Machine learning (ML) has emerged as a transformative solution for CQA optimization by enabling data-driven, predictive, and adaptive release testing frameworks. By integrating diverse datasets ranging from flow cytometry and imaging to multi-omics and process analytics ML models can identify hidden patterns, predict CQA outcomes, and flag potential anomalies earlier in the manufacturing pipeline. Supervised learning models enhance predictive accuracy for potency and viability, while unsupervised and deep learning techniques reveal complex biological heterogeneity. This convergence not only accelerates release testing but also minimizes batch failures, reduces costs, and strengthens compliance through explainable and auditable AI systems. Moreover, ML-driven CQA optimization aligns with regulatory frameworks such as FDA and EMA quality-by-design (QbD) principles, enabling real-time monitoring and continuous process verification. By bridging computational intelligence with biomanufacturing science, machine learning redefines cell therapy release testing, advancing the field toward more resilient, scalable, and patient-focused production systems.